Alibaba Health Loses Ground After a Decade
💡Alibaba Health once led JD Health in traffic and revenue; its reversal reveals how strategy and organization shape AI he
⚡ 30-Second TL;DR
What Changed
In 2025, JD Health reported 73.4 billion yuan in revenue versus Alibaba Health’s 34.3 billion yuan.
Why It Matters
The case suggests that organizational alignment and strategic continuity can matter as much as traffic or platform resources in scaling AI-enabled healthcare businesses. The parallel development of Ant’s healthcare capabilities may also create internal duplication and competition within Alibaba’s broader ecosystem.
What To Do Next
Map Alibaba Health’s and Ant’s healthcare AI capabilities separately—especially 氫離子 and 蚂蚁阿福—before selecting an Alibaba ecosystem partner for a medical AI deployment.
Key Points
- •In 2025, JD Health reported 73.4 billion yuan in revenue versus Alibaba Health’s 34.3 billion yuan.
- •Alibaba Health’s strategic phases moved from O2O, to commerce expansion, to medical services, and back to commerce-led growth.
- •The company changed CEOs four times over roughly a decade, while JD Health maintained a more stable leadership succession.
- •Alibaba Health shut down the Yilu app and returned to Taobao traffic, while delaying commercialization of internal AI products.
- •Ant Group is independently expanding healthcare through Haodafu Online, a self-operated pharmacy, and the Ant Afu AI model.
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
Weekly AI briefing
One email a week. Unsubscribe anytime.